Q1 2024 Earnings Call April 25, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations ...

The biopharmaceutical giant topped its earnings and revenue estimates thanks to strong sales of its HIV, liver disease, and ...

Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $73.00. Salveen Richter has given his Hold rating due to a ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, which serves as the ...

A $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the big biotech dealt a final blow to its ...

Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of ...

Emily Field, an analyst from Barclays, maintained the Hold rating on Gilead Sciences (GILD – Research Report). The associated price ...

Gilead Sciences Inc.’s stock dipped 0.2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter ...

Gilead on Thursday reported revenue growth in the first quarter of 2024, driven by the strong sales of its HIV, cancer and ...

Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of ...

Foster City, California Monday, April 29, 2024, 12:00 Hrs [IST] ...